$VKTX vs $LLY in terms of Safety and tolerability so far based on available data. Conclusion- $VKTX 17.5 mg Is the best Commercial Dose (de-risked PH3) with best tolerability-to-efficacy ratio and is competitive with retatrutide in efficacy and best in class in safety vs retatrutide. Data here ⬇️⬇️ Retatrutide- Safety TRIUMPH‑1 shows: Nausea: 4 mg: 28.6% 9 mg: 38.4% 12 mg: 42.4% Diarrhea: 4 mg: 25.2% 9 mg: 34.1% 12 mg: 32.0% Placebo: 13.5% Constipation: 4 mg: 23.8% 9 mg: 25.9% 12 mg: 26.1% Placebo: 10.9% Vomiting: 4 mg: 10.6% 9 mg: 22.8% 12 mg: 25.3% Placebo: 4.8% Dysesthesia: 4 mg: 5.1% 9 mg: 12.3% 12 mg: 12.5% Placebo: 0.9% Keep in mind- Skin sensitivity event is not a class-wide GLP/GIP feature, could likely be linked to this molecule. Discontinuation due to AEs 4 mg: 4.1% 9 mg: 6.9% 12 mg: 11.3% Placebo: 4.9% Basically, a double-digit discontinuation at 12mg dose a real risk for commercial take. $VKTX Based on Maintenance data reported last week. My focus is primarily on $17.5mg dose Nausea Placebo: ~10–12% 10 mg: ~15–18% 15 mg: ~18–22% 17.5 mg: ~20–25% 20 mg: ~22–28% 22.5 mg: ~25–30% Vomiting Placebo: ~2–3% 10 mg: ~4–6% 15 mg: ~5–7% 17.5 mg: ~6–8%20 mg: ~7–10% 22.5 mg: ~8–12% Diarrhea Placebo: ~8–10% 10 mg: ~10–12% 15 mg: ~12–14% 17.5 mg: ~12–15% 20 mg: ~14–17% 22.5 mg: ~15–18% Discontinuation Due to AEs Placebo: ~3–4% 10 mg: ~3–4% 15 mg: ~4–5% 17.5 mg: ~4–6% 20 mg: ~5–7% 22.5 mg: ~6–8% Key point: The 17.5 mg discontinuation rate is essentially placebo‑like safety.